Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LS ± RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1) veterans initiating hepatitis C virus therapy.

Next Previous
X
Search
Trial Profile

A study to evaluate the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LS ± RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1) veterans initiating hepatitis C virus therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Jul 2017 Data from two prospective studies, one investigator sponsored (Ain et al.) and 1 registration trial (Isakov et al.), and three retrospective RWC (Deutsches Hepatitis C-Register, Madrid Coinfection Registry (Madrid-CoRe), and Veterans Affairs HCV Registry) used to assess effectiveness of the single tablet regimen of ledipasvir/sofosbuvir for 8 weeks in HCV genotype (GT) 1 patients with HIV/HCV coinfection; results presented at the 9th International AIDS Society Conference on HIV Science
    • 27 Dec 2016 New trial record
    • 30 Oct 2016 Results (n=996) presented at the IDWeek 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top